Literature DB >> 27496630

Outcomes Using a Conservative Versus Liberal Red Blood Cell Transfusion Strategy in Infants Requiring Cardiac Operation.

Jill M Cholette1, Michael F Swartz2, Jeffrey Rubenstein3, Kelly F Henrichs4, Hongyue Wang5, Karen S Powers3, L Eugene Daugherty3, George M Alfieris2, Francisco Gensini2, Neil Blumberg4.   

Abstract

BACKGROUND: The optimal hemoglobin for infants after cardiac operation is unknown. Red blood cells (RBCs) are commonly transfused to maintain high hemoglobin concentrations in the absence of a clinical indication. We hypothesized that infants can be managed with a postoperative conservative RBC transfusion strategy, resulting in lower daily hemoglobin concentrations, without evidence of impaired oxygen delivery (ie, lactate, arteriovenous oxygen difference [avO2diff]), or adverse clinical outcomes.
METHODS: Infants weighing 10 kg or less undergoing biventricular repair or palliative (nonseptated) operation were randomly assigned to either a postoperative conservative or liberal transfusion strategy. Conservative group strategy was RBC transfusion for a hemoglobin less than 7.0 g/dL for biventricular repairs or less than 9.0 g/dL for palliative procedures plus a clinical indication. Liberal group strategy was RBC transfusion for hemoglobin less than 9.5 g/dL for biventricular repairs or less than 12 g/dL for palliative procedures regardless of clinical indication.
RESULTS: After the operation of 162 infants (82 conservative [53 biventricular, 29 palliative], 80 liberal [52 biventricular, 28 palliative]), including 12 Norwood procedures (6 conservative, 6 liberal), daily hemoglobin concentrations were significantly lower within the conservative group than the liberal group by postoperative day 1 and remained lower for more than 10 days. The percentage of patients requiring a RBC transfusion, number of transfusions, and volume of transfusions were all significantly lower within the conservative group. Despite lower hemoglobin concentrations within the conservative group, lactate, avO2diff, and clinical outcomes were similar.
CONCLUSIONS: Infants undergoing cardiac operation can be managed with a conservative RBC transfusion strategy. Clinical indications should help guide the decision for RBC transfusion even in this uniquely vulnerable population. Larger multicenter trials are needed to confirm these results, and focus on the highest risk patients would be of great interest.
Copyright © 2017 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27496630     DOI: 10.1016/j.athoracsur.2016.05.049

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  14 in total

1.  Hemoglobin Level at Stage 1 Discharge has No Impact on Inter-stage Growth and Stability in Single Ventricle Infants.

Authors:  Claudia Delgado-Corcoran; Deborah U Frank; Stephanie Bodily; Chong Zhang; Katherine H Wolpert; Kathryn Lucas; Theodore J Pysher; Angela P Presson; Susan L Bratton
Journal:  Pediatr Cardiol       Date:  2017-08-03       Impact factor: 1.655

2.  Restrictive compared with liberal red cell transfusion strategies in cardiac surgery: a meta-analysis.

Authors:  Nadine Shehata; Nikhil Mistry; Bruno R da Costa; Tiago V Pereira; Richard Whitlock; Gerard F Curley; David A Scott; Gregory M T Hare; Peter Jüni; C David Mazer
Journal:  Eur Heart J       Date:  2019-04-01       Impact factor: 29.983

Review 3.  Transfusion thresholds for guiding red blood cell transfusion.

Authors:  Jeffrey L Carson; Simon J Stanworth; Jane A Dennis; Marialena Trivella; Nareg Roubinian; Dean A Fergusson; Darrell Triulzi; Carolyn Dorée; Paul C Hébert
Journal:  Cochrane Database Syst Rev       Date:  2021-12-21

Review 4.  Recent innovations in perfusion and cardiopulmonary bypass for neonatal and infant cardiac surgery.

Authors:  David Sturmer; Claude Beaty; Sean Clingan; Eric Jenkins; Whitney Peters; Ming-Sing Si
Journal:  Transl Pediatr       Date:  2018-04

5.  Recommendations on RBC Transfusion in General Critically Ill Children Based on Hemoglobin and/or Physiologic Thresholds From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Allan Doctor; Jill M Cholette; Kenneth E Remy; Andrew Argent; Jeffrey L Carson; Stacey L Valentine; Scot T Bateman; Jacques Lacroix
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

6.  Recommendations on the Indications for RBC Transfusion for the Critically Ill Child Receiving Support From Extracorporeal Membrane Oxygenation, Ventricular Assist, and Renal Replacement Therapy Devices From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Melania M Bembea; Ira M Cheifetz; James D Fortenberry; Timothy E Bunchman; Stacey L Valentine; Scot T Bateman; Marie E Steiner
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

7.  Recommendations on RBC Transfusion in Infants and Children With Acquired and Congenital Heart Disease From the Pediatric Critical Care Transfusion and Anemia Expertise Initiative.

Authors:  Jill M Cholette; Ariane Willems; Stacey L Valentine; Scot T Bateman; Steven M Schwartz
Journal:  Pediatr Crit Care Med       Date:  2018-09       Impact factor: 3.624

Review 8.  Transfusion Strategies for Pediatric Cardiac Surgery: A Meta-Analysis and Trial Sequential Analysis.

Authors:  Zhi Xiang Duan; Dong Xu Chen; Bao Zhong Yang; Xuan Qiang Zhang
Journal:  Pediatr Cardiol       Date:  2021-05-28       Impact factor: 1.655

9.  Transfusion Practices in Pediatric Cardiac Surgery Requiring Cardiopulmonary Bypass: A Secondary Analysis of a Clinical Database.

Authors:  Sheila J Hanson; Oliver Karam; Rebecca Birch; Ruchika Goel; Ravi M Patel; Martha Sola-Visner; Bruce S Sachais; Ronald G Hauser; Naomi L C Luban; Jerome Gottschall; Cassandra D Josephson; Jeanne E Hendrickson; Matthew S Karafin; Marianne E Nellis
Journal:  Pediatr Crit Care Med       Date:  2021-11-01       Impact factor: 3.624

10. 

Authors: 
Journal:  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz       Date:  2020-08       Impact factor: 1.595

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.